Aidoc
Clinical AI for imaging triage, delivered through aiOS, an enterprise AI operating system that handles data normalization, continuous performance monitoring, and governance so health systems can run multi condition AI without re architecting infrastructure. In January 2026 the FDA cleared what the company describes as healthcare's first comprehensive AI triage solution, powered by CARE (Clinical AI Reasoning Engine), its self developed foundation model. The clearance brought 11 newly cleared indications together with three previously cleared into a single abdomen CT workflow, 14 in total, and per the FDA reviewed pivotal study the new indications reported a mean sensitivity of 97 percent and mean specificity of 98 percent, with the company reporting roughly an order of magnitude reduction in false alerts against single condition tools. The company reports more than 100 million patient cases analyzed on aiOS. A successor model, CARE2, has been announced, and a multi year collaboration with Amazon Web Services supports the foundation model work. Co founded and led by Elad Walach.
Capability Axes
The detection models are the product and the company built its own foundation model to produce them. CARE is not a wrapper on third party models; it is self developed and is what the FDA reviewed.
Unusually specific. The foundation model is named (CARE, for Clinical AI Reasoning Engine), its architectural rationale is explained against single task models, a successor version CARE2 is publicly announced, and the compute partnership supporting it is disclosed. Model versioning is visible rather than inferred, which is exactly what this axis asks for.
Performance figures come from an FDA reviewed pivotal study rather than a vendor benchmark: mean sensitivity of 97 percent, reaching 98.5 percent, and mean specificity of 98 percent, reaching 99.7 percent on some indications. The company additionally reports roughly an order of magnitude reduction in false alerts against leading single condition tools, which is the metric that determines whether a triage product survives real world use rather than being muted by radiologists. Deployment scale is reported at more than 100 million patient cases analyzed.
The January 2026 clearance is the first FDA clearance of a double digit set of acute indications powered by a single foundation model, per the company and corroborated in trade coverage. Eleven newly cleared indications were combined with three existing into a 14 indication abdomen CT triage workflow. Positioning is precise: the company states clearly which indications are cleared, and its earlier announcement of the underlying submission described it as under review rather than cleared.
aiOS is described as providing continuous performance monitoring and built in governance for every model running on it, including models from other vendors, which is a real operational control and rare to state. Held back from A because no bias or subgroup performance evaluation and no third party AI audit were retrieved.
No public pricing. Contact the vendor. Enterprise agreements with health systems; no published rate card.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Contact the vendor
|
Enterprise platform and module agreements | — | — | Vendor Published |
Enterprise agreements with health systems for the aiOS platform and cleared modules. No rate card published. Buyers should establish whether pricing is per module, per scan volume, or platform level, since aiOS also hosts third party AI modules and the economics differ.